Core Insights - Eurobio Scientific reported a revenue of €168 million for the fiscal year ending December 31, 2025, marking a 9% increase from €154.2 million in 2024, with a pro forma growth of 2.3% when excluding acquisition impacts [3][4] Financial Performance - Revenue growth was primarily driven by an increase in France, contributing €5.2 million, influenced by non-recurring factors such as Chikungunya and Dengue epidemics and the extension of certain tenders in Transplantation [3] - The GenDx subsidiary generated €33.5 million in revenue, reflecting a 9% increase in 2025 [3] - Proprietary products accounted for 35% of total revenue, with a growth of over 20% compared to 2024 [6] - International sales represented 42% of total revenue, attributed to acquisitions and significant growth in the U.S. and Canada [7] Strategic Developments - The Group is focused on geographic and technological expansion, aiming to become a major player in specialty diagnostics [5] - Recent acquisitions include Quimark and the Life Sciences unit of Voden Medical Instruments Spa, contributing €1.2 million and €4.1 million to revenue, respectively [10] - A distribution agreement with Seegene generated approximately €48 million in revenue for fiscal year 2025, with discussions ongoing regarding the transition as the agreement nears expiration [11][12] Future Outlook - Eurobio Scientific is committed to accelerating its strategic priorities, including the development of proprietary products and international market expansion [13]

Core Insights - Eurobio Scientific reported consolidated results for the first half of fiscal year 2025, showing a revenue increase of 10.4% compared to the same period in 2024, driven by recent acquisitions and a higher share of proprietary products [2][5][7]. Financial Performance - Revenue reached €81.2 million, up from €73.5 million in the first half of 2024, with a comparable growth of €4.5 million (+6.1%) when excluding acquisitions [4][5]. - Adjusted gross margin improved by 14% to €38.2 million, reflecting a gross margin of 47.4%, up from 45.6% in the previous year [4][10]. - EBITDA decreased to €13.2 million from €13.9 million year-over-year, while operating income fell to €10.3 million from €11.2 million [12]. - Net income dropped by 40% to €2.4 million compared to €4 million in the first half of 2024 [13]. Cost Structure - Cost of goods sold increased by 8% to €43 million, while research and development expenses decreased by 27% to €2.1 million [4][11]. - Sales and marketing expenses surged by 52% to €18.1 million, attributed to strengthening sales teams and scope effects from acquisitions [4][11]. - General and administrative expenses remained stable at €7.7 million, including costs related to the transfer of production lines [11]. Cash Flow and Debt - Free cash flow declined to €4.4 million, impacted by changes in working capital and net investment flows [14]. - As of June 30, 2025, the company had cash and cash equivalents of €26.7 million and financial debt of €11.3 million, resulting in net debt of €2.2 million [15]. Strategic Outlook - Eurobio Scientific aims to increase the share of proprietary products to around 50% of its revenue over the next four years, focusing on product development and international expansion [16].